Stockscreener 앱 받기
14.51
0.62%
-0.09
전일 마감가:
$14.60
열려 있는:
$14.58
하루 거래량:
118.84K
Relative Volume:
0.54
시가총액:
$488.51M
수익:
$99.99M
순이익/손실:
$-21.47M
주가수익비율:
-21.99
EPS:
-0.6597
순현금흐름:
$-11.34M
1주 성능:
+10.34%
1개월 성능:
+3.42%
6개월 성능:
+36.24%
1년 성능:
+17.97%
1일 변동 폭
$14.08
$14.59
1주일 범위
$13.27
$14.98
52주 변동 폭
$7.5625
$18.98
뉴로페이스 Stock (NPCE) Company Profile
명칭
Neuropace Inc
전화
(650) 237-2700
주소
455 N. BERNARDO AVENUE, MOUNTAIN VIEW
Compare NPCE vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NPCE
Neuropace Inc
|
14.51 | 488.51M | 99.99M | -21.47M | -11.34M | -0.6597 |
ABT
Abbott Laboratories
|
101.83 | 176.95B | 44.33B | 6.50B | 7.40B | 3.717 |
SYK
Stryker Corp
|
332.07 | 127.18B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
86.42 | 110.95B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
61.86 | 91.93B | 20.08B | 2.89B | 3.66B | 1.9391 |
EW
Edwards Lifesciences Corp
|
80.84 | 46.61B | 6.07B | 1.06B | 1.34B | 1.8063 |
뉴로페이스 Stock (NPCE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-28 | 개시 | H.C. Wainwright | Buy |
| 2025-01-21 | 개시 | UBS | Buy |
| 2024-03-14 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2024-01-30 | 개시 | Leerink Partners | Outperform |
| 2023-11-10 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-08-24 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2023-02-22 | 개시 | Lake Street | Buy |
| 2022-04-06 | 개시 | Wolfe Research | Outperform |
| 2022-01-19 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-11 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-08-18 | 개시 | Robert W. Baird | Outperform |
| 2021-05-17 | 개시 | JP Morgan | Overweight |
| 2021-05-17 | 개시 | Morgan Stanley | Overweight |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-17 | 개시 | Wells Fargo | Overweight |
모두보기
뉴로페이스 주식(NPCE)의 최신 뉴스
Here's why you should add NeuroPace stock to your portfolio now - MSN
NeuroPace (NPCE) up 0.9% since last earnings report: Can it continue? - MSN
Wall Street analysts see a 41.29% upside in NeuroPace (NPCE): Can the stock really move this high? - MSN
NeuroPace, Inc. (NPCE) stock price, news, quote and history - Yahoo Finance UK
NeuroPace Earnings Call Highlights Growth And AI Push - The Globe and Mail
Here’s why investing in NeuroPace shares could be a smart addition to your portfolio at this time - Bitget
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now - Zacks Investment Research
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High? - sharewise.com
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue? - Yahoo Finance
Wall Street experts predict NeuroPace (NPCE) could climb 41.29%: Is such a surge truly possible for this stock? - Bitget
How Shifting Margin Assumptions Are Rewriting The NeuroPace (NPCE) Investment Narrative - Yahoo Finance
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
NeuroPace Inc urges epilepsy patients to evaluate RNS System through online quiz - Traders Union
Global Neuromodulation Closed-Loop Brain-Computer Interfaces Market Set for 16.4% CAGR Surge Through 2036, Led by the United States, India & China; Key Players Medtronic, NeuroPace, Synchron Drive Algorithm-Centric Innovation - Morningstar
NeuroPace (NPCE) CMO has 1,341 shares withheld for RSU tax - Stock Titan
Aug Selloffs: What makes NeuroPace Inc stock attractive todayMarket Weekly Review & Weekly High Momentum Picks - baoquankhu1.vn
Director at NeuroPace (NPCE) receives 913-share stock grant and controls large fund stake - Stock Titan
NeuroPace director granted 865 shares at $13 | NPCE Insider Trading - Stock Titan
NeuroPace (NPCE) director gets 1,153-share stock grant as board fees - Stock Titan
NeuroPace (NPCE) director receives 1,826-share equity grant in lieu of cash fees - Stock Titan
NeuroPace, Inc. (NPCE) may report negative earnings: Know the trend ahead of next week's release - MSN
Discipline and Rules-Based Execution in NPCE Response - Stock Traders Daily
Analysts Are Bullish on These Healthcare Stocks: Kestra Medical Technologies Ltd. (KMTS), NeuroPace (NPCE) - The Globe and Mail
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company - MarketBeat
Wells Fargo Upgrades NeuroPace(NPCE.US) to Buy Rating, Raises Target Price to $19 - Moomoo
How The NeuroPace (NPCE) Story Is Shifting As Analysts Refresh Valuation Assumptions - Yahoo Finance
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen - MarketBeat
NPCE SEC FilingsNeuropace Inc 10-K, 10-Q, 8-K Forms - stocktitan.net
NeuroPace falls after setback in trial for neuromodulation system - MSN
Published on: 2026-03-12 04:41:05 - baoquankhu1.vn
NeuroPace at Leerink Conference: Strategic Growth and Innovation By Investing.com - Investing.com Canada
NeuroPace to Present at the Leerink Global Healthcare Conference - aijourn.com
Key Factors Expected to Influence NPCE Stock Performance in 2026 - Bitget
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026 - TradingView
NPCE RNS System Explained: Growth Drivers and Setup for 2026 - TradingView
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand - Yahoo Finance
Neuropace (NPCE) chief medical officer sells $399k in stock - Investing.com Nigeria
Behavioral Patterns of NPCE and Institutional Flows - Stock Traders Daily
Published on: 2026-03-09 06:34:24 - baoquankhu1.vn
NeuroPace appoints Patrick Williams as CFO - MSN
Market Outlook: Will NeuroPace Inc stock benefit from M AJuly 2025 Technicals & Technical Buy Zone Confirmation - baoquankhu1.vn
NeuroPace (NASDAQ:NPCE) Upgraded to "Buy" at Wall Street Zen - MarketBeat
Rate Cut: Will NeuroPace Inc stock benefit from M AEarnings Recap Summary & Long Hold Capital Preservation Plans - baoquankhu1.vn
Gains Recap: Is NeuroPace Inc a stock for growth or value investorsJuly 2025 WrapUp & Community Trade Idea Sharing - baoquankhu1.vn
Regulatory Shutdowns Threaten Neuropace’s FDA Approvals and Capital Market Access - The Globe and Mail
NeuroPace revenue up 24% to USD 26.6M in Q4 2025 - Medical Buyer
Boston Scientific to buy Penumbra in $14.5 billion deal - AOL.com
NeuroPace (NASDAQ:NPCE) Stock Rating Upgraded by Cantor Fitzgerald - MarketBeat
뉴로페이스 (NPCE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.44%
0.34%
자본화:
|
볼륨(24시간):